Voquezna (vonoprazan) / Takeda, Otsuka, Phathom Pharma - LARVOL DELTA

Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan. (PubMed, Drug Healthc Patient Saf) - "Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (clinicaltrials.gov) - P4 | N=480 | Completed | Sponsor: Shanghai Jiao Tong University School of Medicine | Recruiting ➔ Completed | Trial completion date: Aug 2026 ➔ Feb 2026 | Trial primary completion date: Aug 2026 ➔ Feb 2026

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

SEVERE HYPOMAGNESEMIA IN A DIABETIC PATIENT ON MULTIPLE LONG-TERM MEDICATIONS (ISN-WCN 2026) - "Vonoprazan, metformin, and semaglutide were discontinued, and intravenous magnesium and calcium supplementation was initiated with concomitant oral alfacalcidol...Vonoprazan was replaced with famotidine...Following withdrawal of the causative drugs and magnesium repletion, both magnesium and calcium levels normalized promptly and remained stable thereafter.Conclusion In diabetic patients on long-term polypharmacy, clinicians should be alert to drug-induced hypomagnesemia. Regular and long-term monitoring of serum magnesium is essential, particularly in those receiving medications that may alter intestinal absorption or hormonal regulation of magnesium homeostasis."

Clinical • Anorexia • Diabetes • Endocrine Disorders • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

Result of Potassium-Competitive Acid Blockers in the Treatment of Severe Gastroesophageal Reflux Disease-Associated Esophageal Ulcer. (PubMed, Cureus) - "As illustrated in the present case, GERD has the potential to progress to esophageal ulceration; therefore, prompt initiation of treatment is necessary. P-CABs may be a useful therapeutic option in similar cases."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (clinicaltrials.gov) - P4 | N=594 | Recruiting | Sponsor: Chinese University of Hong Kong | Trial completion date: Jan 2026 ➔ Jul 2028 | Trial primary completion date: Jan 2026 ➔ Jan 2028

Trial completion date • Trial primary completion date • Gastroenterology • Peptic Ulcer

Helicobacter pylori Management in Older Adults: Current Perspectives From Japan. (PubMed, Korean J Helicobacter Up Gastrointest Res) - "In Japan, vonoprazan-based eradication regimens have become the standard of care because of their high efficacy and pharmacological stability regardless of CYP2C19 genotype...Eradication therapy is highly recommended for disease-specific indications (e.g., peptic ulcer) and for primary prevention of gastric cancer. Overall, older age alone should not be considered a contraindication to eradication therapy; rather, treatment decisions should be based on a comprehensive assessment of comorbidities, concomitant medications, the patient's functional status, and the patient's preferences."

Journal • Review • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor • CYP2C19

Comparative Effectiveness of Vonoprazan Dosing Strategies in Bismuth-Based Quadruple Therapy for Helicobacter pylori Eradication: A Prospective Non-inferiority Cohort Study. (PubMed, Turk J Gastroenterol) - "The remaining drugs (colloidal bismuth pectin, clarithromycin, and amoxicillin) were the same for both groups, with a treatment duration of 14 days. The cost-effectiveness ratios were 2.59 for the QD group and 3.96 for the BID group in the PP analysis, respectively. Vonoprazan 20 mg once daily showed comparable efficacy to twice-daily dosing as part of a bismuth-based quadruple regimen for H. pylori eradication, with better cost-effectiveness, making it a promising option, especially in resource-limited settings."

Head-to-Head • HEOR • Journal • Infectious Disease

Histologic Changes in the Stomach Associated with Potassium-Competitive Acid Blocker (P-CAB) Use (USCAP 2026) - "Background: Potassium-competitive acid blockers (P-CABs), including vonoprazan and tegoprazan, are increasingly used as an alternative to proton pump inhibitors (PPIs) in the treatment of gastroesophageal reflux disease and peptic ulcer disease. Despite mechanistic differences, P-CAB therapy can result in histologic changes in the stomach similar to those seen in patients receiving PPI therapy, including fundic gland dilation and fundic gland polyps. Pathologists should be aware of this association, though analysis of larger cohorts is needed to better define the range of histologic changes that may occur in patients taking P-CABs."

Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Inflammation • Peptic Ulcer • GAST

Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Network Meta-analysis. (PubMed, J Neurogastroenterol Motil) - "Nineteen studies evaluating 5 P-CABs (vonoprazan, tegoprazan, keverprazan, fexuprazan, and zastaprazan) and 2 PPIs (lansoprazole and esomeprazole) were included. P-CABs, especially vonoprazan, showed superior efficacy compared to PPIs in both the initial and maintenance treatment of EE. These findings support the use of P-CABs as a potent and reliable first-line option for EE management, particularly in high-risk populations, with acceptable safety outcomes."

Clinical • Journal • Retrospective data • Review • Gastrointestinal Disorder

Assessing the non-inferiority of a 10-day compared with a 14-day vonoprazan-amoxicillin dual therapy regimen for H. pylori eradication: a systematic review and meta-analysis. (PubMed, BMC Infect Dis) - No abstract available

Head-to-Head • Journal • Retrospective data • Review • Infectious Disease

Helicobacter pylori Eradication Therapy-induced Severe Hypoglycemia in a Hemodialysis Patient with Type 2 Diabetes Mellitus. (PubMed, Intern Med) - "A 48-year-old man with type 2 diabetes mellitus experienced recurrent severe hypoglycemia during hemodialysis induction and received Helicobacter pylori eradication therapy with vonoprazan, amoxicillin, and clarithromycin. He was on repaglinide, which he continued to take even after the discontinuation of empagliflozin...The hypoglycemia resolved after switching to teneligliptin. This case highlights a clinically important but under-recognized risk of severe hypoglycemia associated with vonoprazan-based Helicobacter pylori eradication therapy in patients receiving insulin secretagogues, especially those with advanced renal failure."

Journal • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Renal Disease • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (clinicaltrials.gov) - P=N/A | N=372 | Recruiting | Sponsor: Yanqing Li | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Infectious Disease

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (clinicaltrials.gov) - P=N/A | N=414 | Recruiting | Sponsor: Asian Institute of Gastroenterology, India | Initiation date: Jun 2025 ➔ Dec 2025

Trial initiation date • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. (clinicaltrials.gov) - P=N/A | N=579 | Completed | Sponsor: Nanjing First Hospital, Nanjing Medical University | Recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Jan 2026 | Trial primary completion date: Oct 2026 ➔ Jan 2026

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

Prolonged Radiation-Induced Gastritis Following Yttrium-90 Radioembolization: A Case of Persistent Dyspepsia and Endoscopic Surveillance. (PubMed, Cureus) - "Her symptoms improved with vonoprazan therapy and supportive management. This case thus illustrates delayed gastrointestinal toxicity as a rare complication of hepatic radioembolization."

Journal • Biliary Cancer • Cholangiocarcinoma • Dyspepsia • Gastrointestinal Disorder • Hepatocellular Cancer • Oncology • Solid Tumor

A Case of Gastric Neuroendocrine Tumor With a Raspberry-Like Appearance on the Background of Acid-Suppressive Therapy-Related Gastropathy. (PubMed, DEN Open) - "The medical history of the patient included reflux esophagitis, for which he had been treated with vonoprazan 10 mg daily for 6 years after initially receiving proton pump inhibitors...This case underscores the importance of considering gastric neuroendocrine tumors in the differential diagnosis of raspberry-like gastric lesions, particularly in patients with potent acid-suppressive therapy-related gastropathy. Trial Registration: N/A."

Journal • Gastric Cancer • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Solid Tumor

Vonoprazan mitigates diethyl nitrosamine-induced acute liver injury in mice via modulating p-AMPK/ SIRT1/ PGC-1α and Keap1/Nrf2/HO-1 pathways. (PubMed, Life Sci) - "VON suggests hepatoprotective potential, in a dose dependent manner, possibly due to their antioxidant and anti-inflammatory properties."

Journal • Preclinical • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hepatology • Infectious Disease • Liver Failure • KEAP1 • NFKB1 • SIRT1 • TNFA

PATIENT DEMOGRAPHICS AND BASELINE CLINICAL CHARACTERISTICS IN GASTROESOPHAGEAL REFLUX DISEASE BY VONOPRAZAN TREATMENT DURATION: RESULTS FROM A POST-HOC ANALYSIS OF THE VIEW STUDY (ISPOR 2026) - P=N/A | "Patients requiring 8-week vonoprazan treatment for GERD had distinct baseline demographics, clinical characteristics, and concomitant medication profiles vs those with 4-week treatment."

Clinical • Retrospective data • Cardiovascular • Gastroenterology • Gastroesophageal Reflux Disease • Hypertension

POST HOC ANALYSIS OF PATIENT AND TREATMENT CHARACTERISTICS BY VONOPRAZAN TREATMENT DURATION: RESULTS FROM PATIENTS WITH REFLUX OESOPHAGITIS IN THE VIEW STUDY (ISPOR 2026) - P=N/A | "In patients with RE, baseline demographics, patient characteristics, and concomitant medications influenced vonoprazan treatment duration, whereas the duration of treatment with previous medications did not."

Clinical • Retrospective data • Cardiovascular • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hypertension • Infectious Disease

Efficacy and Safety of Vonoprazan-Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Trial. (PubMed, Helicobacter) - P4 | "All three regimens achieved high eradication rates, with V-DT and V-TT being statistically noninferior to V-BQT. The 10-day V-DT regimen achieved eradication rates comparable to V-BQT with substantially fewer adverse events and reduced antibiotic use, supporting its potential as a simplified first-line option for H. pylori eradication."

Journal • Infectious Disease

Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials. (PubMed, EClinicalMedicine) - "At 8 weeks, zastaprazan 20 mg, vonoprazan 20 mg, and esomeprazole 40 mg demonstrated moderate-certainty superiority over rabeprazole 20 mg and omeprazole 20 mg with RDs ranging from 0.05 to 0.11, while only vonoprazan 20 mg demonstrated moderate-certainty benefit versus lansoprazole 30 mg (RD: 0.04)...Vonoprazan 20 mg and rabeprazole-ER 50 mg demonstrated moderate-certainty benefit compared with pantoprazole 40 mg (RDs: 0.12 and 0.09, respectively).At 24 weeks, vonoprazan 10 mg and 20 mg showed moderate-to-high-certainty benefit versus lansoprazole 15 mg (RDs: -0.11 and -0.13, respectively), while in direct comparisons, esomeprazole 20 mg outperformed lansoprazole 15 mg and pantoprazole 20 mg, with approximately 40-50% relative reductions in recurrence...Comparative trials evaluating newer P-CABs against optimized PPI strategies, including twice-daily dosing, are needed to evaluate efficacy and long-term safety, particularly with respect to hypergastrinemia and infection..."

Journal • Retrospective data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease

Vonoprazan Test for PPI Refractory GERD (clinicaltrials.gov) - P=N/A | N=100 | Enrolling by invitation | Sponsor: Fu Jen Catholic University Hospital

New trial • Gastroenterology • Gastroesophageal Reflux Disease

Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication (clinicaltrials.gov) - P=N/A | N=70 | Not yet recruiting | Sponsor: Peking University First Hospital

New trial • Infectious Disease

A Systematic Review on Exploration of Extracts and Phytochemicals for Peptic Ulcer from 2018 to 2024. (PubMed, Curr Top Med Chem) - "Decoctions or infusions of extracts derived from leaves, vegetables, branches, and flowers have been employed in numerous research studies over the past several decades to examine their various biological functions. The present investigation aims to identify the anti-ulcer properties of botanical medicines in the treatment of ulcers and peptic ulcer disease, as reported in publications between 2018 and 2024."

Journal • Gastroenterology • Gastrointestinal Disorder • Peptic Ulcer

Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial. (PubMed, Lancet Reg Health West Pac) - P4 | "Refractory H. pylori-infected patients with at least two previous treatment failures were randomly assigned (1:1:1; block sizes six) to 10 days vonoprazan-containing (20 mg twice daily) regimens of VA (amoxicillin 1000 mg three times daily); VRA (amoxicillin 1000 mg three times daily, and rifabutin 150 mg twice daily); or BQT (bismuth 110 mg, tetracycline 500 mg, and metronidazole 400 mg, all four times daily). Ten-day VRA therapy is a viable alternative to BQT therapy for H. pylori rescue treatment with fewer adverse events, whereas VA therapy showed unacceptable efficacy. National Natural Science Foundation of China, and Xinyi Digestive Disease Fund Project, College of Digestive Sciences, Shanghai Jiao Tong University School of Medicine."

Head-to-Head • Journal • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease • Neutropenia